Skip to main content
Equibles
AORT logo

AORT · Artivion, Inc.

Track AORT — free

Use AORT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AORT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$19.10 -0.30 (-1.55%) At close · Nov 13
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$931.88M
Shares
48.79M
Volume · Nov 13 558.04K Avg daily vol (3M) 672.56K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$19.10 Open$19.62 Day$18.95–19.81 52W close$19.10–47.18 Avg vol 30d709K Short int3.4M · 7.0% of shares · 7.2d Short vol61% Last earningsNov 5, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 6

Up next

Next earnings call
Feb 11, 2027 Est · unconfirmed · in 13 wks
Q3 2026 earnings call transcript
call held Nov 5, 2026
Play latest call

Latest documents

2026
Nov 6
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rises 9% as core products lead growth

Artivion reported quarterly revenues of $123.8 million for the three months ended September 30, 2026, up 9%, driven primarily by aortic stent grafts and On-X products. Gross margin declined to 61% of revenue from 66%.

Revenue $123.79M ▲ 9.2% Net loss $7.93M Diluted EPS -$0.16
Read from the MD&A section
3 source passages
Artivion, Inc. (“Artivion,” the “Company,” “we,” or “us”), is a leader in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. We reported quarterly revenues of $123.8 million for the three months ended September 30, 2026, a 9% increase from the three months ended September 30, 2025. The increase in revenues for the three months ended September 30, 2026 was primarily due to increases in revenues from aortic stent grafts and On-X products, and to a lesser extent, other products, while revenues from surgical sealants and preservation services remained relatively flat. Gross margin as a percentage of total revenues | 61% | 66% Open the document at this passage
Nov 5
Earnings call
Revenue grew 9% as adjusted EBITDA declined 8%

Artivian reported third-quarter total constant-currency revenue growth of 9% and an adjusted EBITDA decline of 8% year-over-year.

2 source passages
Greetings, and welcome to the Artivian Third Quarter 2026 earnings call. In the third quarter, we delivered total constant currency revenue growth of 9% and adjusted EBITDA decline of 8% year-over-year. Open the document at this passage
Aug 7
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $125.76M ▲ 11.3% Net loss $13.51M Diluted EPS -$0.28
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$481.88M
Trailing 12 months
Net income (TTM)
−$17.59M
Trailing 12 months
Revenue growth YoY
+9.2%
Year over year
Operating margin
2.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-4.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$315.39M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-0.1%
Year over year · fewer shares
Price change (1Y)
-58.1%
Trailing year
Short interest
7.0%
Latest settlement · 7.2 days to cover
View all 125 metrics

Quarterly results

Revenue Net income Net loss
▲3.9% $97.31M −$16.48M '24 Q4* ▲1.6% $98.98M −$505,000 '25 Q1 ▲15.3% $112.97M $1.34M '25 Q2 ▲18.4% $113.39M $6.50M '25 Q3 ▲19.2% $115.99M $2.43M '25 Q4* ▲17.5% $116.34M $1.42M '26 Q1 ▲11.3% $125.76M −$13.51M '26 Q2 LATEST ▲9.2% $123.79M −$7.93M '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

AI Brief

Q3 FY26 earnings call · Nov 5, 2026
Q3 FY26

TL;DR. Artivion grew revenue 9% to $123.8 million in Q3 2026, with On-X up 13%, stent grafts up 12%, rising U.S. AMDS implants after PMA approval, NEXUS launch preparation on track for January 2027 and Artisan trial enrollment at 56 patients. Against that, adjusted EBITDA fell 8% to $22.5 million, gross margin fell to 61.4% from 65.6%, GAAP swung to a $(7.9) million net loss, free cash flow was negative $17.6 million, 2027 carries a 2-point revenue and 4-point EBITDA growth headwind from the Baxter agreement expiration, and the AMDS starter set purchase remains challenging.

Bullish
  • + Total revenue grew 9% to $123.8 million in Q3 2026 from $113.4 million a year earlier
  • + On-X revenue grew 13% year-over-year in Q3 2026
  • + Aortic stent graft revenue grew 12% year-over-year
  • + Preparations for the U.S. commercial launch of NEXUS in January 2027 are progressing well
  • + U.S. AMDS implants increased versus the second quarter following PMA approval, with set-sale hurdles viewed as transient
  • + Artisan (ARCEVO LSA) trial enrollment reached 56 patients and continues on schedule
Bearish
  • − Adjusted EBITDA fell 8% to $22.5 million from $24.6 million
  • − Gross margin fell to 61.4% from 65.6% on mix and Onyx/Nexus manufacturing ramp costs
  • − GAAP swung to a net loss of $(7.9) million, or $(0.16) per diluted share, from $6.5 million net income
  • − Free cash flow was negative $17.6 million versus positive $17.7 million a year ago
  • − 2027 faces a 2 percentage point revenue growth headwind and 4 percentage point EBITDA growth headwind from the completion of the Baxter/Perclot agreement
  • − The AMDS starter set purchase requires $100,000 and has proven more difficult than expected

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −33%
below
Price vs 50-day avg −17%
below
RSI (14) 35
neutral
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −12%
trailing
6-month return −18%
trailing
YTD return −58%
this year
Relative strength −18%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $23 › 200d $28 — 200d above 50d
Institutional flow Accumulating
183 of 206 funds reported for Sep 30 · net +174.8K sh shares · +33 new
Insider flow Distributing
Net -$2.5M over 90 days · 100% sells
Short interest Falling
6.99% of shares out · ▼ -8.6% MoM · 7.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
206 holders — mid 3-yr range
Squeeze score 60
elevated · 0–100
Fundamentals
Excellent
Revenue growth +18%
Y/Y
Gross margin 95%
contracting
EPS growth +166%
Y/Y
Free cash flow $839.0K
Buyback $8.9M
remaining
Balance sheet $150.2M
net debt
Quant / Vol
risk profile
Very High
Volatility 54%
annualized · 1-yr
Max drawdown −60%
past year
ATR 7.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 3 of last 3
Latest guidance · from the 8-K filed Aug 6, 2026
Revenue for the full year 2026 · full year 2026 Non-GAAP $480M – $496M
Adjusted EBITDA for the full year 2026 · full year 2026 Non-GAAP $92M – $99M
Previous outlook earlier release · from the 8-K filed May 7, 2026

Still-open targets the latest release did not restate under the same label.

Adjusted EBITDA · full year 2026 $100M – $107M
Guided vs delivered · last 3 settled
Reported revenues full year 2025
guided $435M – $443M
$441.33M In line
Revenues full year 2024
guided $388M – $396M
$388.54M In line
Revenues full year 2023
guided $331M – $343M
$354M Beat +5.0%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−33% Bearish
Price vs 50-day avg
−17% Bearish
RSI (14)
35 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $23 › 200d $28 — 200d above 50d
Institutional flow Accumulating
183 of 206 funds reported for Sep 30 · net +174.8K sh shares · +33 new
Insider flow Distributing
Net -$2.5M over 90 days · 100% sells
Short interest Falling
6.99% of shares out · ▼ -8.6% MoM · 7.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
206 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $19 Now $19 · 0% Range high $47
vs 200-day avg -33% vs 50-day avg -17%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted diluted income per common share, non-GAAP non-GAAP $0.21 Six Months Ended June 30, 2026 —
Adjusted EBITDA non-GAAP $26.4M second quarter of 2026 —
Adjusted EBITDA, non-GAAP non-GAAP $48.47M Six Months Ended June 30, 2026 —
Adjusted G&A, non-GAAP non-GAAP $119.28M Six Months Ended June 30, 2026 —
Adjusted net income, non-GAAP non-GAAP $10.52M Six Months Ended June 30, 2026 —
EBITDA, non-GAAP non-GAAP $13.78M Six Months Ended June 30, 2026 —
Free cash flows, non-GAAP non-GAAP -$18.86M Six Months Ended June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
AORT
Artivion, Inc.
this stock
$931.88M -58.1% +18.0% — 7.0%
ABT
Abbott Laboratories
 $187.95B -13.4% +5.7% 40.5 1.1%
MDT
Medtronic plc
 $131.57B +7.1% +8.4% 25.3 1.8%
SYK
Stryker Corp
 $117.88B -11.9% +11.2% 33.0 1.7%
BSX
Boston Scientific Corp
 $64.27B -53.5% +12.5% 18.8 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
222
% held
94.5%
Reported
183 of 206
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
227
View
Short & Settlement
Short Interest Falling
Shares short
3.4M
Days to cover
7.2d
Change
-323.1K sh
View
Short Volume
Short vol %
61%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
61
Value
$1.3K
As of
Oct 9, 2026
View
Off-Exchange
Off-exchange %
36.5%
Week of
Oct 5, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$2.5M
Buyers / Sellers
0 / 2
Buyers Sellers
View
Congressional Trades Buy
Member
Gilbert Cisneros
Amount
$1.0K–$15.0K
Traded
Aug 20, 2026
View
Financials
Financials
Revenue (FY)
$441.3M
Net income (FY)
$9.8M
EPS diluted
$0.21
View
Buybacks
Authorized
$15.0M
Remaining
$8.9M
Spent Remaining
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 6, 2026
This year
15

Artivion reported quarterly revenues of $123.8 million for the three months ended September 30, 2026, up 9%, driven primarily by aortic stent grafts and On-X products. Gross margin declined to 61% of revenue from 66%.

View
Proposed Sales
Value
$286.7K
Shares
11.5K
Filed
Sep 10, 2026
View
Exempt Offerings
Offering
$20.0M
Filed
Sep 14, 2020
View
Earnings & Events
Webcasts
Last webcast
Nov 10, 2026
View
Investor Relations
Latest news
Lance A. Berry Brian Johnston
Published
Nov 5, 2026
Upcoming events
5
View

Performance

5D 20D 120D MTD YTD
AORT -5.5% -12.3% -17.6% -15.4% -58.1%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -8.1% -11.1% -18.1% -15.2% -68.7%

Capital returns

Buyback program · as of Sep 30, 2014
Authorized
$15.00M
Spent (derived)
$6.10M
Remaining
$8.90M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 784199 CUSIP 228903100 13F (30d) 170 filings 155 filers Visit website Investor relations